Kither Biotech
Marco Kevin Malisani has a diverse work experience spanning over several industries. Marco Kevin is currently the Co-founder and Executive Director of Kither Biotech, a biopharma company focused on developing new drug candidates for rare pulmonary diseases. In this role, they secured funding for the clinical development of their lead asset, KIT2014, as an add-on therapy for Cystic Fibrosis, and launched the preclinical development of KITCL27 for Idiopathic Pulmonary Fibrosis.
Prior to this, Malisani co-founded and served as the CEO of Kither Biotech from 2019 to 2022. Marco Kevin also has experience as a Senior Advisor at Compass Banca S.p.A. - Gruppo Mediobanca from 2017 to 2019 and as the COO/Deputy CEO of CreditAccess Asia NV from 2013 to 2016.
Additionally, Malisani has worked as the Lead Investment Manager at DOB Equity, overseeing equity investments in East Africa from 2010 to 2013. Marco Kevin served as the CEO and Director of Investments at Sofia SGR in 2008, and as a Principal at MKI-Ventures from 1999 to 2007.
Earlier in their career, Malisani was an Assistant Director at CVC Capital Partners, evaluating investments in Europe and completing three acquisitions. Marco Kevin also held roles at European Vinyls Corporation, including Corporate Finance and Investor Relations Manager and Strategic Planning Manager. Marco Kevin began their career as an Associate at Goldman Sachs.
Overall, Malisani has a strong background in biopharma, finance, and investment management, with a track record of successfully securing funding and overseeing projects in various industries.
Marco Kevin Malisani attended Harvard University, where they earned their AB degree in Economics. Marco Kevin later pursued further education at INSEAD, where they obtained an MBA degree with a focus on Business Administration and Management.
This person is not in any teams
This person is not in any offices
Kither Biotech
Kither Biotech is a pharmaceutical product company that focuses its R&D activities on the development of new drugs. The R&D activities of the company mainly involve the development of new drugs to treat chronic inflammatory diseases.In recent years Kither has focused its first line of activities on the development of a small peptide(KIT2014) developed internally for the treatment of cystic fibrosis, a disease that predominantly affects the lungs and that currently has no cure. The KIT2014 peptide was assigned the Orphan Drug designation from the European Medicines Agency. The KIT2014 compound is currently undergoing the pre-clinical phase of clinical development.Kither’s product portfolio also includes a molecule (CL27), also developed internally, that is being developed for the treatment of Chronic Obstructive Pulmonary Diseases and Allergic Asthma. The company is about to start the pre-clinical phase of development of the CL27 molecule.